(Q46912038)

26 December 2017

title

Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis (English)

1 reference

26 December 2017

0 references

1

1 reference

26 December 2017

author name string

Williams JV

series ordinal

2

1 reference

26 December 2017

Metz LM

series ordinal

3

1 reference

26 December 2017

publication date

6 November 2007

1 reference

26 December 2017

Multiple Sclerosis Journal

published in

1 reference

26 December 2017

volume

14

1 reference

26 December 2017

issue

3

1 reference

26 December 2017

page(s)

406-411

1 reference

26 December 2017

Burns in a suicide attempt related to psychiatric side effects of interferon

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458507082942

Side effects of high-dose interferon therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507082942

A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507082942

Long term recombinant interferon alpha treatment in MS with special emphasis to side effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507082942

Psychiatric complications of long-term interferon alfa therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507082942

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507082942

Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507082942

Suicidal ideation during interferon-alpha2b and ribavirin treatment of patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507082942

Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507082942

Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507082942

Interferon beta1a and depression in secondary progressive MS: data from the SPECTRIMS Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507082942

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507082942

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507082942

The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507082942

Emotional state of patients with relapsing-remitting MS treated with interferon beta-1b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507082942

Reasons for antidepressant prescriptions in Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507082942

Long-term emotional state of multiple sclerosis patients treated with interferon beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507082942

A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507082942

Influence of Interferon beta treatment on quality of life in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507082942

Psychiatric disorders and depression in multiple sclerosis outpatients: impact of disability and interferon beta therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507082942

Longitudinal course of depression symptoms in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507082942

The Goldman Consensus statement on depression in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507082942

Antidepressant pharmacotherapy of depression associated with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507082942

Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507082942

Fluvoxamine treatment of major depression associated with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507082942

21 January 2018

Identifiers

DOI

10.1177/1352458507082942

1 reference

26 December 2017

1 reference

26 December 2017